Home Articles List Article Information
Iranian Journal of Pharmaceutical Research
Journal Archive
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Fathi-Moghaddam, H., Shafiee Ardestani, M., Saffari, M., Jabbari Arabzadeh, A., Elmi, M. (2010). The Selective Cyclooxygenase-2 Inhibitor, the Compound 11b Improves Haloperidol Induced Catatonia by Enhancing the Striatum Dopaminergic Neurotransmission. Iranian Journal of Pharmaceutical Research, Volume 9(Number 4), 387-393.
Hadi Fathi-Moghaddam; Mehdi Shafiee Ardestani; Mostafa Saffari; Ali Jabbari Arabzadeh; Mitra Elmi. "The Selective Cyclooxygenase-2 Inhibitor, the Compound 11b Improves Haloperidol Induced Catatonia by Enhancing the Striatum Dopaminergic Neurotransmission". Iranian Journal of Pharmaceutical Research, Volume 9, Number 4, 2010, 387-393.
Fathi-Moghaddam, H., Shafiee Ardestani, M., Saffari, M., Jabbari Arabzadeh, A., Elmi, M. (2010). 'The Selective Cyclooxygenase-2 Inhibitor, the Compound 11b Improves Haloperidol Induced Catatonia by Enhancing the Striatum Dopaminergic Neurotransmission', Iranian Journal of Pharmaceutical Research, Volume 9(Number 4), pp. 387-393.
Fathi-Moghaddam, H., Shafiee Ardestani, M., Saffari, M., Jabbari Arabzadeh, A., Elmi, M. The Selective Cyclooxygenase-2 Inhibitor, the Compound 11b Improves Haloperidol Induced Catatonia by Enhancing the Striatum Dopaminergic Neurotransmission. Iranian Journal of Pharmaceutical Research, 2010; Volume 9(Number 4): 387-393.

The Selective Cyclooxygenase-2 Inhibitor, the Compound 11b Improves Haloperidol Induced Catatonia by Enhancing the Striatum Dopaminergic Neurotransmission

Article 8, Volume 9, Number 4, Autumn 2010, Page 387-393  XML PDF (322 K)
Document Type: Research article
Authors
Hadi Fathi-Moghaddam1; Mehdi Shafiee Ardestani2; Mostafa Saffari3; Ali Jabbari Arabzadeh1; Mitra Elmi4
1Depattment of Physiology and Physiology Research Center, School of Medicine, Jondishapour University of Medical Sciences, Ahwaz, Iran.
2Department of HIV and Hepatitis B and Nanobiotechnology,Pasteur Institute of Iran, Tehran, Iran.
3Department of Pharmaceutics, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4Department of Pharmacology, Razi institute for drug research, College of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Abstract
A substantial amount of evidence has proposed an important role for Cyclooxygenase-2 (COX-2) enzyme in brain diseases and affiliate disorders. The purpose of this research was studying the effects of COX-2 selective inhibition on haloperidol-induced catatonia in an animal model of drug overdose and Parkinson’s disease (PD). In this study, the effect of acute and Sub-chronic oral administration of a new selective COX-2 inhibitor, i.e. the compound 11b or 1-(Phenyl)-5-(4-methylsulfonylphenyl)-2-ethylthioimidazole, in a dosage of 2, 4 and 8 mg/kg on haloperidol-induced catatonia was evaluated and compared to the standard drug scopolamine (1 mg/kg) by microanalysis of Striatum dopaminergic neurotransmission. The results showed a very high potency for 11b in improving the catalepsy by enhancing the dopaminergic neurotranmission (p < 0.05). In addition, statistical analysis showed the dose- and time-dependent behavior of the observed protective effect of 11b against the haloperidol-induced catatonia and enhancement of the dopaminergic neurotransmission. These findings are additional pharmacological data that suggest the effectiveness of COX-2 inhibition in treatment of schizophreny-associated rigidity.
Keywords
Catalepsy; Nigrostriatal; Compound 11b; Dopaminergic neurotransmission
Statistics
Article View: 7,671
PDF Download: 16,117